UNASSIGNED: The use of @entity2494 ( @entity2494 ) may improve ovarian stimulation outcomes in @entity1 of advanced reproductive age and could reduce embryo aneuploidy. In this prospective study, 48 @entity1 diagnosed with poor ovarian response received @entity2494 supplementation for at least 12 weeks. These @entity1 were compared with a group of poor responders (n = 113) who did not receive supplementation. During the study period, @entity1 taking day 2 FSH and @entity53 were measured monthly before and after treatment. Stimulation characteristics, stimulation outcome and clinical outcome (clinical pregnancy and live birth rates) were reported. Evaluation of anti-M  llerian hormone ( @entity248 ) was carried out before initiation of treatment and immediately before the subsequent stimulation. Supplementation with @entity2494 for at least 12 weeks resulted in a modest, but statistically significant, increase in @entity248 levels and decrease in baseline FSH (P < 0.001 and P = 0.007, respectively). Administration of @entity2494 had no effect on any of the stimulation parameters nor was there any difference in clinical pregnancy rates and live birth rates between the two groups. Supplementation with @entity2494 significantly affects @entity1 with poor prognosis undergoing ovarian stimulation for IVF. @entity1 should be counselled about the uncertain effectivenessm, potential side-effects and cost of this treatment.

XXXX administration before IVF in poor responders: a prospective cohort study.

@entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients'] @entity2494 :: ('MESH:D003687', 'Chemical') :: ['DHEA', 'dehydroepiandrosterone'] @entity248 :: ('268', 'Gene') :: ['AMH'] @entity53 :: ('MESH:D004958', 'Chemical') :: ['oestradiol']
@entity2494 :: (MESH:D003687,Chemical) :: ['Dehydroepiandrosterone']
